Bruker Corporation

BRKR Healthcare Medical Devices

Bruker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, up 2.08% from fiscal 2024. In the quarter to June 2026, revenue grew 5.15%, EPS fell 920.0%, free cash flow grew 28.6% and total debt fell 25.1%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for five.

54.80 1.74 −3.08%
Market cap
$8.6B
P/E
0.0×
Fwd P/E
55.7×
Dividend yield
0.36%
F-score
4/9
Altman Z
2.43
Beneish M
−2.56
Dividend safety
34/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

4 4 3 5
ROE
(1.11%) (1.05%) (1.69%) (5.07%)
ROA
(0.38%) (0.37%) (0.60%) (1.73%)
ROIC
0.96% 1.05% 0.73% (0.47%)
Return on Tangible Assets
(1.30%) (1.34%) (2.48%) (6.16%)
Average Days of Receivables
58.47 57.88 57.28 56.94
Free Cash Flow per Share
(0.07) 0.29 0.34 0.62
Free Cash Flow
(10.60) 43.30 51.30 93.90
Capital Expenditures
(104.90) (90.80) (89.00) (96.50)
Other line items
Cash ROIC
(0.22%) 0.93% 1.20% 2.13%
Accounts Receivable Turnover
6.31 6.19 6.40 6.55
Accounts Payable Turnover
8.82 8.26 7.37 8.46
Inventory Turnover
1.50 1.72 1.69 1.60
Average Days of Payables
37.04 42.39 51.91 38.97
Days of Inventory on Hand
240.36 214.94 216.33 218.02
Tax Rate
(3.25) (1.33) (1.23) 1.80
Research and Development Expense of Revenue
11.63% 11.50% 11.55% 11.24%
Selling, General and Administrative Expense of Revenue
27.53% 27.54% 27.85% 27.74%
Share Based Compensation of Revenue
0.00% 2.22% 0.00% 0.00%
Operating CF/Net income
(3.98) (5.96) (3.85) (1.78)
Depreciation/Fixed assets
0.29 0.30 0.32 0.32
Capex/Depreciation
(0.49) (0.41) (0.39) (0.42)
Revenue per Share
22.65 22.64 22.72 22.98
Operating CF per Share
0.62 0.88 0.92 1.25
Capex per Share
(0.69) (0.60) (0.58) (0.63)
Capex to Sales
0.03 0.03 0.03 0.03

Fold the line items

Columns are period end dates